Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China

Table 2 Neutralization sensitivity of the HIV-1 B’ isolates to the plasmas from HIV-1 CRF07_BC infected patients

Virus (co-receptor usage)	Neutralizing activity (ID50 titer, 1/x) of plasma from HIV-1 CRF07_BC infected patients
Virus (co-receptor usage)	XJ256P	XJ257P	XJ0135P	XJ6291P	XJ6371P	XJ0793P	XJ1353P	XJ1981P	Mean
AH096V (R5)	―	―	10	10	28	―	―	―	11.0
AH104V (X4R5)	―	―	―	―	13	―	―	―	8.6
AH259V ( R5)	―	―	―	―	―	―	―	―	―
AH311V (X4R5)	―	―	10	―	27	―	―	―	10.6
AH374V (X4R5)	―	―	―	368	―	―	―	―	53.0
AH968V (R5)	―	―	―	―	35	―	―	―	11.4
AH419V (R5)	―	―	―	―	―	―	―	―	―
AH628V (R5)	―	―	―	―	―	―	13	―	8.6
AH634V (R5)	20	―	―	11	18	―	24	―	13.1
AH691V (R5)	16	―	―	―	―	≥ 648	41	22	94.9
AH1188V (X4R5)	16	20	―	―	20	10	29	24	16.9
AH1597V (R5)	18	―	54	10	21	―	17	―	18.0
Mean	11.2	9.0	12.2	38.6	16.8	61.5	15.0	10.5
SF33(X4R5)*	160	≥ 648	―	―	236	304	56	316

The plasmas were tested at a series of 3-fold dilutions ranging from 1:8 to 1:648. “―” means that the neutralizing titer is “≤ 8”. For calculation, the ID50 titers (1/x) of ≤ 8 and ≥ 648 were treated as 8 and 648, respectively. *A laboratory-adapted HIV-1 strain was included as a control.

ISSN: 1743-422X